UroGen Pharma (NASDAQ:URGN) Shares Up 4.5% – Time to Buy?

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) rose 4.5% during mid-day trading on Wednesday . The company traded as high as $10.91 and last traded at $11.11. Approximately 12,087 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 500,716 shares. The stock had previously closed at $10.63.

Wall Street Analyst Weigh In

URGN has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday, March 10th. HC Wainwright lowered their price objective on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $38.20.

UroGen Pharma Stock Performance

The firm has a market capitalization of $485.37 million, a price-to-earnings ratio of -3.34 and a beta of 0.80. The company has a 50-day moving average of $10.72 and a 200-day moving average of $11.45. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. On average, equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Wellington Management Group LLP raised its position in shares of UroGen Pharma by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 146,953 shares of the company’s stock valued at $1,565,000 after purchasing an additional 9,653 shares during the period. Toronto Dominion Bank bought a new position in UroGen Pharma during the 4th quarter valued at about $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in UroGen Pharma by 2.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after purchasing an additional 36,084 shares in the last quarter. Vestal Point Capital LP raised its position in shares of UroGen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after acquiring an additional 1,230,000 shares during the last quarter. Finally, Stonepine Capital Management LLC boosted its stake in UroGen Pharma by 15.7% in the fourth quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock valued at $3,454,000 after acquiring an additional 43,979 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.